Bli medlem
Bli medlem

Du är här


Biocartis Group NV: Disclosure of outstanding voting securities

Press release - Regulated information

Mechelen, Belgium,
11 April 2016
- Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative molecular
diagnostics company (Euronext Brussels: BCART), today announces that 45,000
new shares were issued as a result of the exercise of stock options under the
2013 Plan for employees, consultants and management members.

In view hereof, in accordance with article 15 of the Belgian Act of 2 May 2007
on the disclosure of major shareholdings in issuers' shares of which are
admitted to trading on a regulated market and laying down miscellaneous
provisions (the 'Belgian Act'), the outstanding share capital and outstanding
voting securities of the Company can be summarised as follows:

* Total outstanding share capital: EUR 405,891.88;
* Total outstanding voting securities: 40,589,188 shares;
* Total outstanding voting rights: 40,589,188 voting rights;
* Shares that can still be issued: 5,366,935 shares (each share entailing one
voting right), of which: * 859,172 shares can be issued upon the exercise
of 859,172 outstanding stock options (each stock option having the form of
a warrant) that are still outstanding under the '2013 Plan' for employees,
consultants and management members, entitling the holders thereof to
acquire one new share per option; * 262,934 shares can be issued upon the
exercise of 262,934 outstanding stock options (each stock option having the
form of a warrant) that are still outstanding under the '2015 Plan' for
employees, consultants, management members and directors, entitling the
holders thereof to acquire one new share per option; * 67,000 shares can be
issued upon the exercise of 67,000 warrants, called 'WHC Warrants', granted
to Whitemarsh Capital LLC, a commercial partner of Biocartis, with each
warrant exercisable into one share; * 4,177,829 shares can be issued
pursuant to a conversion option agreement entered into between Koninklijke
Philips N.V. ('Philips') and the Company[1].

[1] The conversion option agreement allows Philips to convert certain royalty
and other payments due to it up to a maximum of 10% of the then outstanding
capital of the Company on a fully diluted post-money basis, but only if the
Company has not yet made a lump sum payment in lieu of such royalty and other
payments, and the conversion can only be exercised by Philips upon the
acceptance of the exercise by the Company at its sole discretion. The number
of 4,177,829 shares that can still be issued assumes that all outstanding
warrants (entailing the issue of up to 1,189,106 new shares) have been
exercised, it being understood that the actual number of shares issuable
depends on a number of factors.

Pursuant to the Belgian Act and the articles of association of the Company, a
notification to the Company and the Belgian Financial Services and Markets
Authority (FSMA) is required by all natural and legal persons in each case
where the percentage of voting rights attached to the securities held by such
persons in the Company reaches, exceeds or falls below the threshold of 3%,
5%, 10%, and every subsequent multiple of 5%, of the total number of voting
rights in the Company.

----- END ----

More information:

Renate Degrave
Corporate Communications and Investor Relations
+32 15 631 729

About Biocartis
Biocartis (Euronext Brussels: BCART) is an innovative molecular diagnostics
(MDx) company providing next generation diagnostic solutions aimed at
improving clinical practice for the benefit of patients, clinicians, payers
and industry. Biocartis' proprietary MDx Idylla(TM) platform is a fully
automated sample-to-result, real-time PCR (Polymerase Chain Reaction) system
that offers accurate, highly reliable molecular information from virtually
any biological sample in virtually any setting. Idylla(TM) addresses the
growing demand for personalized medicine by allowing fast and effective
treatment selection and treatment progress monitoring. Biocartis launched the
Idylla(TM) platform in September 2014. Biocartis is developing and marketing
a rapidly expanding test menu addressing key unmet clinical needs in oncology
and infectious diseases. These areas represent respectively the fastest
growing and largest segments of the MDx market worldwide. Today, Biocartis
has four oncology tests and one test for infectious diseases on the market.
More information:


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Biocartis Group NV via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.